Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

EMANATE: uno studio sul setmelanotide nei pazienti con varianti genetiche specifiche nel percorso MC4R

19 ottobre 2026 aggiornato da: Rhythm Pharmaceuticals, Inc.

Uno studio di fase 3, randomizzato, in doppio cieco, controllato con placebo: molteplici sottostudi indipendenti su setmelanotide in pazienti con varianti del gene POMC/PCSK1, LEPR, NCOA1(SRC1) o SH2B1 nel percorso del recettore della melanocortina-4

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

  • Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a)
  • Leptin receptor (LEPR; Sub-study 035b)
  • Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 [SCR1]; Sub-study 035c)
  • Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

296

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alberta
      • Edmonton, Alberta, Canada, T6G 2E1
        • University of Alberta - Alberta Diabetes Institute (ADI)
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
      • Lyon, Francia, 69677
        • GH Est Hopital Femme Mere Enfant
      • Paris, Francia, 75651
        • Hu Pitie Salpetriere Aphp
      • Paris, Francia, 75771
        • Hopital Armand Trousseau
      • Pessac, Francia, 33604
        • Centre Hospitalier Universitaire (CHU) de Bordeaux
      • Saint-Denis, Francia, 97400
        • Hôpital Félix Guyon Bellepierre
      • Toulouse, Francia
        • CHU de Toulouse Hopital des Enfants
      • Berlin, Germania, 10117
        • Charite - Universitatsmedizin Berlin
      • Frankfurt, Germania, 60596
        • Endokrinologikum Frankfurt
      • Leipzig, Germania, 04103
        • Universitaetsklinikum Leipzig
      • Ulm, Germania, 89075
        • Universitaetsklinikum Ulm
      • Rio, Grecia, 26504
        • University of Patras School of Medicine
      • Petah Tikva, Israele, 49372
        • Hasharon Hospital
      • Ramat Gan, Israele, 52621
        • Chaim Sheba MC, Safra Children's Hospital
      • Rotterdam, Olanda, 3015 GD
        • Erasmus Medisch Centrum
      • San Juan, Porto Rico, 00925-253
        • University of Puerto Rico
      • San Juan, Porto Rico, 00927
        • Puerto Rico Consortium for Clinical Investigation, Inc.
      • Bristol, Regno Unito, BS2 8AE
        • Bristol Royal Hospital for Children
      • Cambridge, Regno Unito, CB2 0QQ
        • University of Cambridge
      • Liverpool, Regno Unito, L9 7AL
        • Aintree University Hospital
      • London, Regno Unito, W2 1NY
        • Imperial College Healthcare Trust
      • London, Regno Unito, NW1 2PG
        • London Medical - The London Diabetes Centre
      • London, Regno Unito, WC1E6JF
        • University College London Hospitals NHS Foundation Trust
      • Manchester, Regno Unito, M13 9WL
        • Manchester Children's Hospital
      • Barcelona, Spagna, 08950
        • Hospital Sant Joan de Deu, Barcelona
      • Cadiz, Spagna
        • Puerta del Mar University Hospital
      • Madrid, Spagna, 28040
        • Hospital Fundación Jimenez Díaz
      • Málaga, Spagna, 29010
        • Hospital Universitario Virgen de la Victoria de Málaga
      • Valencia, Spagna, 46014
        • Hospital General de Valencia
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85016
        • Phoenix Children's Hospital
      • Scottsdale, Arizona, Stati Uniti, 85258
        • HonorHealth Bariatric Center
    • California
      • Los Angeles, California, Stati Uniti, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06519
        • Yale Center for Clinical Investigation
    • Florida
      • Altamonte Springs, Florida, Stati Uniti, 32701
        • Advent Health
      • Gainesville, Florida, Stati Uniti, 32610
        • University of Florida
    • Georgia
      • Suwanee, Georgia, Stati Uniti, 30024
        • InQuest Medical Research
    • Massachusetts
      • Worcester, Massachusetts, Stati Uniti, 01655
        • UMASS Memorial Medical Center
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48105
        • University of Michigan
      • Dearborn, Michigan, Stati Uniti, 48126-2619
        • Metro Detroit Endocrinology Center
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55902
        • Mayo Clinic
    • Mississippi
      • Madison, Mississippi, Stati Uniti, 39110
        • Mississippi Center for Advanced Medicine
    • Missouri
      • Chesterfield, Missouri, Stati Uniti, 63017
        • St. Luke's Hospital
      • Kansas City, Missouri, Stati Uniti, 64108
        • Children's Mercy
      • St Louis, Missouri, Stati Uniti, 63130
        • Washington University in St. Louis
    • New York
      • Buffalo, New York, Stati Uniti, 14260
        • University of Buffalo
      • New York, New York, Stati Uniti, 10032
        • Columbia University
      • New York, New York, Stati Uniti, 10029
        • Mount Sinai Hospital
      • New York, New York, Stati Uniti, 10029
        • Metropolitan Hospital Center
      • Staten Island, New York, Stati Uniti, 10306
        • Ten's Medical Center - Pediatric Endocrinology Clinic
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Stati Uniti, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Danville, Pennsylvania, Stati Uniti, 17822
        • Geisinger Clinic
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • UPMC Montefiore
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Vanderbilt University School of Medicine
    • Texas
      • Amarillo, Texas, Stati Uniti, 79106
        • Texas Tech
      • Houston, Texas, Stati Uniti, 77030
        • Texas Children's Hospital
      • Houston, Texas, Stati Uniti, 77084
        • Biopharma Informatic
      • McAllen, Texas, Stati Uniti, 78503
        • Rio Grande Valley Endocrine Center
      • Plano, Texas, Stati Uniti, 75093
        • Endocrine Associates of Dallas and Plano
    • Washington
      • Tacoma, Washington, Stati Uniti, 98405
        • MultiCare Health System Institute for Research and Innovation
    • West Virginia
      • Morgantown, West Virginia, Stati Uniti, 26506
        • West Virginia University
    • Wisconsin
      • Marshfield, Wisconsin, Stati Uniti, 54449
        • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 6 anni a 65 anni (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Participants must have a pre-identified:

    • Heterozygous genetic variant in the POMC gene or PCSK1 gene
    • Heterozygous genetic variant in the LEPR gene
    • Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
    • Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
  • Between 6 and 65 years of age at the time of provision of informed consent/assent

  • Obesity, defined as body mass index (BMI) ≥30 kg/m^2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 up to 17 years of age

  • Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent

  • Participant and/or parent or guardian reports that participant experienced childhood obesity, defined as the participant and/or parent or guardian reporting that the participant had obesity or was significantly overweight during childhood

  • Agree to use a highly effective form of contraception throughout the study and for 90 days following the study

  • Reported history of lifestyle intervention of diet and exercise

  • Symptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.

Key Exclusion Criteria:

  • Weight loss of 2% or greater in the previous 3 months
  • Bariatric surgery or procedure within the previous 6 months
  • Significant psychiatric disorder(s)
  • Suicidal ideation, attempt or behavior
  • Clinically significant pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
  • Glycated hemoglobin (HbA1C) >10% at Screening
  • History of significant liver disease or severe kidney disease
  • History or close family history (parents or siblings) of melanoma, or participant history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant hypersensitivity to any excipient in the study drug
  • If female, pregnant or breastfeeding

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: POMC or PCSK1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Sperimentale: LEPR variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Sperimentale: NCOA1 (SRC1) variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Sperimentale: SH2B1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
Lasso di tempo: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters [m])^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.

Baseline, Week 52

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
Lasso di tempo: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
Lasso di tempo: Baseline, Week 52

Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration

Baseline, Week 52
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
Lasso di tempo: Baseline, Week 52

Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
Lasso di tempo: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
Lasso di tempo: Baseline, Week 52

BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
Lasso di tempo: Baseline, Week 52

The percentage change from baseline in BMI 95th percentile was calculated as ([BMI at Week 52 / BMI 95th percentile]) - [BMI at baseline / BMI 95th percentile])*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Waist Circumference
Lasso di tempo: Baseline, Week 52

The waist circumference (in centimeters [cm]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Lasso di tempo: Baseline up to 60 weeks

TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Baseline up to 60 weeks
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
Lasso di tempo: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
Lasso di tempo: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
Lasso di tempo: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
Lasso di tempo: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
Lasso di tempo: Baseline, Week 52

Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Cattedra di studio: David Meeker, MD, Rhythm Pharmaceuticals, Inc.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

26 aprile 2022

Completamento primario (Effettivo)

19 dicembre 2025

Completamento dello studio (Effettivo)

30 giugno 2026

Date di iscrizione allo studio

Primo inviato

30 settembre 2021

Primo inviato che soddisfa i criteri di controllo qualità

13 ottobre 2021

Primo Inserito (Effettivo)

26 ottobre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • RM-493-035

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .